MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, CARM had $778K increase in cash & cash equivalents over the period. $1,908K in free cash flow.

Cash Flow Overview

Change in Cash
$778K
Free Cash flow
$1,908K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Accounts payable
    • Stock-based compensation expense
    • Payment of principal related to ...
    • Reduction in the operating right...
Negative Cash Flow Breakdown
    • Deferred revenue
    • Accrued expenses
    • Payment of finance liability fro...
    • Others

Cash Flow
2025-09-30
2025-06-30
Net income (loss)
44,717 -19,040
Depreciation and amortization expense
0 661
Stock-based compensation expense
421 939
Reduction in the operating right of use assets
32 1,233
Write-off of deferred financing costs
0 208
Loss on sale of assets held for sale
320 -3,539
Gain (loss) on sale of property and equipment
0 113
Non-cash interest expense
0 31
Loss on abandonment of operating lease right-of-use asset
0 927
Gain on sale of sale-leaseback
0 -
Prepaid expenses and other assets
805 -3,328
Accounts payable
1,140 1,951
Accrued expenses
-1,438 -4,922
Deferred revenue
-41,250 -3,729
Operating lease liabilities
-589 -1,041
Other long term liabilities
0 57
Net cash used in operating activities
1,908 -15,971
Proceeds from sales of assets held for sale
0 163
Proceeds from sales of property and equipment
0 524
Purchases of property and equipment
0 0
Net cash provided by (used in) investing activities
0 687
Payment of principal related to finance lease liabilities
-60 304
Proceeds from failed sale-leaseback arrangement
0 0
Payment of finance liability from failed sale-leaseback arrangements
1,190 327
Proceeds from the exercise of stock options
0 5
Sale of common stock under open market sale agreement, net of issuance costs
0 0
Net cash (used in) provided by financing activities
-1,130 -626
Net decrease in cash, cash equivalents and restricted cash
778 -15,910
Cash and cash equivalents at beginning of period
17,909 -
Cash and cash equivalents at end of period
2,777 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net income (loss)$44,717K Accounts payable$1,140K Stock-based compensationexpense$421K Reduction in the operatingright of use assets$32K Net cash used inoperating activities$1,908K Canceled cashflow$44,402K Net decrease incash, cash...$778K Canceled cashflow$1,130K Deferred revenue-$41,250K Accrued expenses-$1,438K Prepaid expenses andother assets$805K Operating leaseliabilities-$589K Loss on sale of assetsheld for sale$320K Payment of principalrelated to finance lease...-$60K Net cash (used in)provided by financing...-$1,130K Canceled cashflow$60K Payment of financeliability from failed...$1,190K

Carisma Therapeutics Inc. (CARM)

Carisma Therapeutics Inc. (CARM)